DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Information source: Allergan
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Anti-biotic Resistance

Intervention: moxifloxacin 0.5% HCI ophthalmic solution (Drug); gatifloxacin ophthalmic solution 0.3% (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Allergan

Official(s) and/or principal investigator(s):
Medical Director, Study Director, Affiliation: Allergan


The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Basic Science

Primary outcome: Percentage of Subjects With Strain Resistance of the Conjunctiva as Determined by Minimum Inhibitory Concentration (MIC) at Day 14

Secondary outcome:

Mutant Prevention Concentration (MPC) of the Conjunctiva at Day 14

Minimum Inhibitory Concentration 50 (MIC50) at Day 14

Minimum Inhibitory Concentration 90 (MIC90) at Day 14

Minimum Inhibitory Concentration (MIC) Range at Day 14


Minimum age: 50 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Male or Female

- At least 50 years of age

- In good general health

Exclusion Criteria:

- Any ocular surgery or use of topical antibiotics or antiseptics in either eye within

the last 3 months

- Use of topical steroids, or non-steroidal anti inflammatory drugs in either eye

within 30 days of Baseline (or anticipated during the study)

- Use of lid scrubs within 7 days of Baseline in either eye (or anticipated use during

the study)

Locations and Contacts

Minneapolis, Minnesota, United States

Saskatoon, Saskatchewan, Canada

Additional Information

Starting date: March 2009
Last updated: November 16, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017